- Home
- SRFM vs SABS Comparison
SRFM vs SABS Comparison
Compare SRFM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | SABS |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.7M | 181.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRFM | SABS |
|---|---|---|
| Price | $3.29 | $3.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.81 | ★ $9.80 |
| AVG Volume (30 Days) | ★ 4.7M | 265.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $108,158,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $1.00 |
| 52 Week High | $9.91 | $6.60 |
Technical Indicators
Market Signals| Indicator | SRFM | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 71.50 | 56.55 |
| Support Level | $1.88 | $3.56 |
| Resistance Level | $3.14 | $3.83 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 86.26 | 60.55 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.